Clinomics Secures 'Dream Cancer Drug' Cancer Vaccine Technology... Integration of Bioinformatics and AI

Subsidiary's 'Customized Cancer Vaccine System' Comprising 7 Patents
Over 30% Higher Immune Response Prediction Accuracy Compared to Existing Technologies

Genome-based healthcare specialist Clinomics announced on the 23rd that its subsidiary Zeromics has succeeded in developing a 'personalized cancer vaccine system' technology.

The cancer vaccine technology, consisting of a total of seven patents, demonstrated an immune response accuracy over 30% higher than existing technologies. According to a comparative analysis of evaluation data comprising melanoma, lung cancer, colorectal cancer, gastric cancer, and pancreatic cancer, the company stated that it secured the highest accuracy among current technologies.

Founded in 2021, Zeromics is an AI-based new drug development specialist for anticancer and anti-aging treatments and serves as the first step for Clinomics' entry into disease therapeutic development.

Cancer vaccines are personalized treatments with fewer side effects that administer cancer-specific substances (mutations) to patients, awakening the patient's natural immune system for therapy. When used in combination with existing immune checkpoint inhibitors, they provide optimized therapeutic responsiveness for cancer patients and are called the 'dream anticancer drug.' However, accurately and precisely designing neoantigens, the starting point of cancer vaccine development, remains highly competitive.

Zeromics is a bioinformatics technology specialist company that analyzes ultra-large biological data using AI technology. It has developed the ‘NeoPro-Onco’ technology, which predicts neoantigens with ultra-high precision, a key factor influencing the effectiveness of cancer treatments. Unlike existing technologies that predict immunogenicity using only some properties of neoantigens, this technology simultaneously analyzes the maximum number of neoantigen characteristics and biological processes involved in immunogenicity (existing 9 factors + new 9 biomarkers + new 11 differential factors). It improved the immune accuracy of autoimmune therapy triggered by neoantigens. Additionally, it integratively and intelligently analyzes factors affecting how cancer neoantigens stimulate the body's own immunity and applies a total of nine individual AI algorithms to secure high immune response accuracy. Based on this, Zeromics has completed patent applications for seven cases related to algorithms and new biomarkers.

When evaluating immunogenicity positive predictive value, which is important in clinical and medical settings, using evaluation data consisting of melanoma and lung cancer, Zeromics' technology showed 50% and 33.3% higher accuracy than existing technologies in the top 10 and top 20 positive predictive values, respectively. It secured high immunogenicity accuracy with 9 out of 10 (90%) and 16 out of 20 (80%) predictions in the top 10 and top 20 results, respectively. In evaluation data consisting of colorectal cancer, gastric cancer, and pancreatic cancer, it also secured 33.3% and 25% higher accuracy than existing technologies, confirming that Zeromics' technology shows the highest positive predictive value across multiple cancer types.

In line with the trend of immune checkpoint inhibitors becoming widespread, Clinomics and Zeromics plan to develop technologies that apply more precise cancer vaccine technology to achieve higher therapeutic effects across various cancer types.

Yoonseong Cho, CEO of Zeromics, said, "The core of immune-utilizing cancer treatments is securing cancer vaccines with high immunogenicity of neoantigens injected into patients," adding, "Achieving high therapeutic efficacy along with low side effects through accurate neoantigen prediction is important." He emphasized, "Cancer vaccines can be applied to all cancer types where neoantigens occur," and "Our goal is to develop cancer vaccines for all cancer types."

Jonghwa Park, CEO of Clinomics, explained, "The future lies in technology that removes cancer through patient-specific personalized neoantigens." He added, "We will connect liquid biopsy technology for cancer analysis with our subsidiary's cancer vaccine development technology," and said, "Our business strategy is to develop cancer diagnosis and treatment products that can predict and diagnose cancer early by drawing blood even when healthy, and provide personalized cancer vaccines when cancer occurs."